HSIC vs TERN · P/E 24, rev $12.67B vs $6.12B cap
Henry Schein Inc (HSIC) versus Terns Pharmaceuticals Inc (TERN) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ.
Latest reported HSIC revenue for 2024-12-28 was $12.67B. Net income was $398.0M. Revenue was up 2.7% from 2023-12-30 to 2024-12-28. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Latest reported TERN revenue for 2022-12-31 was $0. Net income was -$60.3M. TERN currently screens at market cap $6.12B.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. TERN currently screens at market cap $6.12B.
Not investment advice. Open the HSIC and TERN stock pages for the full models.
Not investment advice.